Clinical trials: PEComa
Lymphangioleiomyomatosis
LAM Pilot Study With Imatinib Mesylate
This is a phase 1 clinical trial comparing imatinib mesylate to placebo for individuals with lymphangioleiomyomatosis (LAM).
- Trial name
- LAMP-1 (NCT03131999)
- Testing
- Imatinib Mesylate 400Mg Capsule
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Advanced Malignant Neoplasm, Castleman Disease
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body…
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease
- Trial name
- NCT01552434
- Testing
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- M.D. Anderson Cancer Center
Pulmonary Disease, Oropharyngeal Disease
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
This study will examine bacteria and toxins in the mouth, lung and digestive system that may be the cause of various diseases or symptoms. H.
- Conditions
- Pulmonary Disease, Oropharyngeal Disease, Lymphangioleiomyomatosis, Pulmonary Fibrosis
- Trial name
- NCT00366509
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
PEComa, Malignant, TSC1
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation
Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a…
- Conditions
- PEComa, Malignant, TSC1, TSC2, mTOR Pathway Abberation
- Trial name
- NCT03817515
- Testing
- ABI-009
- Sponsor
- Aadi Bioscience, Inc.
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Selective Endovascular Embolization of Kidney Artery
Superselective Renal Artery Embolization for Renal Angiomyolipoma
To evaluate the efficacy and safety of selective endovascular embolization in the treatment of renal angiomyolipoma (AML). Materials and Methods: A prospective analysis will be conducted on patients who undergo transcatheter…
- Trial name
- EAL (NCT07538908)
- Testing
- Selective endovascular embolization of kidney artery
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Botkin Hospital
Leiomyomatosis
Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)
Pulmonary lymphoangioleiomyomatosis (LAM) is a rare destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor.
- Trial name
- NCT00001869
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphangioleiomyomatosis
Safety and Durability of Sirolimus for Treatment of LAM
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of…
- Trial name
- MIDAS (NCT02432560)
- Testing
- Sirolimus, Everolimus
- Where
- 20 sites in United States
- Volunteers
- 600 people
- Sponsor
- University of Cincinnati
Uterine Sarcoma, Uterine Leiomyosarcoma
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas.
- Conditions
- Uterine Sarcoma, Uterine Leiomyosarcoma, Endometrial Stromal Sarcoma, ESS
- Trial name
- NCT07467772
- Testing
- Elacestrant
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Lymphangioleiomyomatosis
National Lymphangioleiomyomatosis Registry, France
RE-LAM-CE is a registry of lymphangioleiomyomatosis cases in France. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in France, including demographic information and information concerning the…
- Trial name
- RE-LAM-CE (NCT01484236)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Vincent COTTIN
Lymphangioleiomyomatosis, Pulmonary Hypertension
Pulmonary Hypertension in Lymphangioleiomyomatosis
This is a descriptive study of patients with Lymphangioleiomyomatosis and precapillary pulmonary hypertension.
- Trial name
- LAM-PH (NCT00960895)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Nonmalignant Neoplasm, Tuberous Sclerosis
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
This research study is evaluating a drug called rapamycin as a possible treatment for the lumps (or tumors) that form in the kidneys, called angiomyolipomas, in people who have either TSC or LAM.
- Conditions
- Nonmalignant Neoplasm, Tuberous Sclerosis, Lymphangioleimyomatosis, Kidney Angiomyolipoma
- Trial name
- NCT00126672
- Testing
- Rapamycin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Safety of Simvastatin in LAM and TSC
The purpose of this research study is to see if simvastatin can be taken safely in patients with either LAM or TSC, who are already being treated with everolimus or sirolimus.
- Trial name
- SOS (NCT02061397)
- Testing
- Simvastatin, Sirolimus Oral Product, Everolimus Oral Product
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
Lung Diseases, Lymphangiomyomatosis
Lymphangioleiomyomatosis (LAM) Registry
To establish a registry of individuals with LAM by forming a consortium of six clinical centers and referring physicians who treat LAM patients.
- Trial name
- NCT00005486
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Lymphangioleiomyomatosis, a Study on Cathepsin K
This is a physiopathological case-control, non-interventional, monocentric study of adult patients with lymphangioleiomyomatosis.
- Trial name
- LAM-CAK (NCT05323370)
- Testing
- 24h urine, urine sample
- Where
- France
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Tuberous Sclerosis, Lymphangioleiomyomatosis
TSC Biosample Repository and Natural History Database
The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database.
- Trial name
- NCT05676099
- Testing
- Phlebotomy, Buccal (cheek) swab, Genetic Testing
- Where
- 26 sites in United States, Canada
- Volunteers
- 5,000 people
- Sponsor
- National Tuberous Sclerosis Association
Lymphangioleiomyomatosis, Lymphangiomyomas
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM), a disease primarily of women of child-bearing age, is characterized by cystic lung disease and abdominal tumors (e.g., angiomyolipomas).
- Conditions
- Lymphangioleiomyomatosis, Lymphangiomyomas, Pleural Effusions, Ascites
- Trial name
- NCT00005906
- Testing
- Octreotide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypomelanotic Macules, Facial Angiofibroma
Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)
International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long´-term variability of these biomarker/s
- Conditions
- Hypomelanotic Macules, Facial Angiofibroma, Shagreen Patches, Ungual Fibromas
- Trial name
- TuScCom (NCT02654340)
- Where
- 8 sites in Albania, Egypt and 6 more
- Volunteers
- 20 people
- Sponsor
- CENTOGENE GmbH Rostock
Pulmonary Lymphangioleiomyomatosis
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Lymphangioleiomyomatosis (LAM) is a rare lung disease that mostly affects women of childbearing age. In LAM, abnormal, muscle-like cells begin to grow out of control in the lungs.
- Trial name
- NCT02116712
- Testing
- Saracatinib
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Tony Eissa
Lymphangioleiomyomatosis (LAM)
COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
The investigators will perform a two-center phase I trial of celecoxib (COX-2 inhibitor) administered at 200mg by mouth daily for 6 months. Up to 12 adult women with LAM will be recruited (between 4-8 at each site).
- Trial name
- COLA (NCT02484664)
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brigham and Women's Hospital